Clinical Trial Update: Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the addition of IPdR, a radiation-sensitizing drug, to standard capecitabine-based chemoradiation for locally advanced rectal cancer; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Adenocarcinoma
• Rectal Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• IPdR

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Locally Advanced Rectal Carcinoma, Rectal Adenocarcinoma | Phase 1 | Status: TERMINATED | Results posted: 2023-10-05